[1] E. W. Steyerberg, Clinical prediction models : a practical approach to development, validation, and updating. Springer, 2019.
[2] J. Hippisley-Cox, C. Coupland, and P. Brindle, ‘Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study’, BMJ, vol. 357, 2017.
[3] P. P. Glasziou and L. M. Irwig, ‘An evidence based approach to individualising treatment’, BMJ, vol. 311, no. 7016, pp. 1356–1359, Nov. 1995, doi: 10.1136/bmj.311.7016.1356.
[4] J. A. N. Dorresteijn et al., ‘Estimating treatment effects for individual patients based on the results of randomised clinical trials’, BMJ, vol. 343, p. d5888, Oct. 2011, doi: 10.1136/bmj.d5888.
[5] B. Brown, S. Cheraghi-Sohi, T. Jaki, T.-L. Su, I. Buchan, and M. Sperrin, ‘Understanding clinical prediction models as “innovations”: a mixed methods study in UK family practice’, BMC Med. Inform. Decis. Mak., Dec. 2016, doi: 10.1186/s12911-016-0343-y.
[6] M. A. Hernán, J. Hsu, and B. Healy, ‘Data science is science’s second chance to get causal inference right: A classification of data science tasks’, CHANCE, vol. 32, no. 1, pp. 42–49, Jan. 2018, doi: 10.1080/09332480.2019.1579578.
[7] A. D. Hingorani and P. Vallance, ‘A simple computer program for guiding management of cardiovascular risk factors and prescribing’, BMJ, vol. 318, no. 7176, pp. 101–105, Jan. 1999.
[8] A.-H. Patomella et al., ‘General practitioners’ reasoning on risk screening and primary prevention of stroke – a focus group study’, BMC Fam. Pract., vol. 19, no. 1, p. 190, Dec. 2018, doi: 10.1186/s12875-018-0883-6.
[9] D. M. Lloyd-Jones et al., ‘Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among Medicare Patients: The Million Hearts Longitudinal ASCVD Risk Assessment Tool: A Special Report From the American Heart Association and American College of Cardiology’, Circulation, vol. 135, no. 13, pp. e793–e813, Mar. 2017, doi: 10.1161/CIR.0000000000000467.
[10] M. Sperrin, K. Diaz-Ordaz, and R. Pajouheshnia, ‘Invited Commentary: Treatment drop-in: making the case for causal prediction’, Am. J. Epidemiol., Feb. 2021, doi: 10.1093/aje/kwab030.
[11] N. van Geloven et al., ‘Prediction meets causal inference: the role of treatment in clinical prediction models’, Apr. 2020, Accessed: Apr. 21, 2020. [Online]. Available: http://arxiv.org/abs/2004.06998
[12] F. J. Candido dos Reis et al., ‘An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation’, Breast Cancer Res., vol. 19, no. 1, p. 58, Dec. 2017, doi: 10.1186/s13058-017-0852-3.
[13] L. Lin, M. Sperrin, D. A. Jenkins, G. P. Martin, and N. Peek, ‘A scoping review of causal methods enabling predictions under hypothetical interventions’, Diagn. Progn. Res., vol. 5, no. 1, p. 3, Feb. 2021, doi: 10.1186/s41512-021-00092-9.
[14] S. Wells et al., ‘Cohort Profile: The PREDICT cardiovascular disease cohort in New Zealand primary care (PREDICT-CVD 19)’, Int. J. Epidemiol., vol. 46, no. 1, Feb. 2017, doi: 10.1093/ije/dyv312.
[15] R. Pylypchuk et al., ‘Cardiovascular disease risk prediction equations in 400 000 primary care patients in New Zealand: a derivation and validation study.’, Lancet Lond. Engl., vol. 391, no. 10133, pp. 1897–1907, May 2018, doi: 10.1016/S0140-6736(18)30664-0.
[16] P. Velentgas, N. A. Dreyer, P. Nourjah, S. R. Smith, and M. M. Torchia, Eds., Developing a Protocol for Observational Comparative Effectiveness Research: A User’s Guide. Rockville (MD): Agency for Healthcare Research and Quality (US), 2013. Accessed: Mar. 11, 2022. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK126190/
[17] D. B. Rubin, ‘The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials’, Stat. Med., vol. 26, no. 1, pp. 20–36, Jan. 2007, doi: 10.1002/sim.2739.
[18] T. J. VanderWeele and I. Shpitser, ‘A new criterion for confounder selection’, Biometrics, vol. 67, no. 4, pp. 1406–1413, Dec. 2011, doi: 10.1111/j.1541-0420.2011.01619.x.
[19] J. Pearl, ‘Remarks on the method of propensity score’, Stat. Med., vol. 28, no. 9, pp. 1415–1416; author reply 1420-1423, Apr. 2009, doi: 10.1002/sim.3521.
[20] D. Westreich and S. Greenland, ‘The Table 2 Fallacy: Presenting and Interpreting Confounder and Modifier Coefficients’, Am. J. Epidemiol., vol. 177, no. 4, pp. 292–298, Feb. 2013, doi: 10.1093/aje/kws412.
[21] M. A. Hernán and J. M. Robins, Causal inference: what if. Boca Raton: Chapman & Hall/CRC, 2020.
[22] J. M. Robins, M. A. Hernán, and B. Brumback, ‘Marginal structural models and causal inference in epidemiology.’, Epidemiol. Camb. Mass, vol. 11, no. 5, pp. 550–60, Sep. 2000.
[23] M. A. Hernán, B. Brumback, and J. M. Robins, ‘Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men.’, Epidemiol. Camb. Mass, vol. 11, no. 5, pp. 561–70, Sep. 2000.
[24] R. P. Ames, ‘Antihypertensive drugs and lipid profiles’, Am. J. Hypertens., vol. 1, no. 4, pp. 421–427, 1988, doi: 10.1093/ajh/1.4.421.
[25] P. Strazzullo, S. M. Kerry, A. Barbato, M. Versiero, L. D’Elia, and F. P. Cappuccio, ‘Do statins reduce blood pressure? A meta-analysis of randomized, controlled trials’, Hypertension, vol. 49, no. 4, pp. 792–798, Apr. 2007, doi: 10.1161/01.HYP.0000259737.43916.42.
[26] K. N. Karmali et al., ‘Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: An Overview of Systematic Reviews’, JAMA Cardiol., vol. 1, no. 3, pp. 341–349, Jun. 2016, doi: 10.1001/jamacardio.2016.0218.
[27] H. Yousuf et al., ‘Effectiveness of web-based personalised e‑Coaching lifestyle interventions’, Neth. Heart J., vol. 27, no. 1, pp. 24–29, Jan. 2019, doi: 10.1007/s12471-018-1200-7.
[28] T. Brett et al., ‘The Fremantle Primary Prevention Study: a multicentre randomised trial of absolute cardiovascular risk reduction’, Br. J. Gen. Pract., vol. 62, no. 594, pp. e22–e28, Jan. 2012, doi: 10.3399/bjgp12X616337.
[29] N. E. M. Jaspers et al., ‘Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people’, Eur. Heart J., vol. 41, no. 11, pp. 1190–1199, Mar. 2020, doi: 10.1093/eurheartj/ehz239.
[30] M. Sperrin, G. P. Martin, A. Pate, T. Van Staa, N. Peek, and I. Buchan, ‘Using marginal structural models to adjust for treatment drop-in when developing clinical prediction models’, Stat. Med., vol. 37, no. 28, pp. 4142–4154, Dec. 2018, doi: 10.1002/sim.7913.
[31] D. M. Kent et al., ‘The PATH Statement Explanation and Elaboration Document’, Ann. Intern. Med., vol. 172, no. 1, pp. W1–W25, Jan. 2020, doi: 10.7326/M18-3668.
[32] S. Wager and S. Athey, ‘Estimation and Inference of Heterogeneous Treatment Effects using Random Forests’, J. Am. Stat. Assoc., vol. 113, no. 523, pp. 1228–1242, Jul. 2018, doi: 10.1080/01621459.2017.1319839.
[33] A. M. Alaa and M. van der Schaar, ‘Bayesian Inference of Individualized Treatment Effects using Multi-task Gaussian Processes’, in Advances in Neural Information Processing Systems, 2017, vol. 30. Accessed: Aug. 13, 2021. [Online]. Available: https://papers.nips.cc/paper/2017/hash/6a508a60aa3bf9510ea6acb021c94b48-Abstract.html
[34] R. H. H. Groenwold et al., ‘Explicit inclusion of treatment in prognostic modeling was recommended in observational and randomized settings’, J. Clin. Epidemiol., vol. 78, pp. 90–100, Apr. 2016, doi: 10.1016/j.jclinepi.2016.03.017.
[35] Z. Xu et al., ‘Prediction of cardiovascular disease risk accounting for future initiation of statin treatment’, Am. J. Epidemiol., vol. X, no. X, p. X, 2021.
[36] D. Westreich, J. K. Edwards, C. R. Lesko, S. R. Cole, and E. A. Stuart, ‘Target Validity and the Hierarchy of Study Designs’, Am. J. Epidemiol., vol. 188, no. 2, pp. 438–443, Feb. 2019, doi: 10.1093/aje/kwy228.
[37] D. Westreich, J. K. Edwards, C. R. Lesko, E. Stuart, and S. R. Cole, ‘Transportability of Trial Results Using Inverse Odds of Sampling Weights’, Am. J. Epidemiol., vol. 186, no. 8, pp. 1010–1014, 2017, doi: 10.1093/aje/kwx164.
[38] B. A. Dickerman and M. A. Hernán, ‘Counterfactual prediction is not only for causal inference’, Eur. J. Epidemiol., vol. 35, no. 7, pp. 615–617, Jul. 2020, doi: 10.1007/s10654-020-00659-8.